Published in Circ Cardiovasc Genet on April 14, 2011
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events | NCT00239681
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect. PLoS One (2012) 0.92
A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysis. PLoS One (2011) 0.92
Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One (2012) 0.84
Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease. Med Sci Monit (2014) 0.81
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. J Am Heart Assoc (2012) 0.79
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. J Pers Med (2012) 0.77
Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises. Curr Atheroscler Rep (2011) 0.76
KIF6 719Arg Genetic Variant and Risk for Thoracic Aortic Dissection. Aorta (Stamford) (2016) 0.75
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol (2011) 0.75
Lack of association of KIF6 genotype with vascular disease and statin response. Circ Cardiovasc Genet (2011) 0.75
No evidence for cardiac dysfunction in Kif6 mutant mice. PLoS One (2013) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem (2007) 4.45
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet (2010) 3.24
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet (2009) 3.06
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet (2008) 2.85
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) (2009) 2.56
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics (2003) 2.49
On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women's Genome Health Study. PLoS Genet (2010) 2.48
Statin adherence and risk of accidents: a cautionary tale. Circulation (2009) 2.47
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf (2008) 2.42
Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med (2013) 2.39
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation (2009) 2.26
A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. Arch Intern Med (2007) 2.20
Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol (2012) 2.14
Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making (2006) 2.12
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol (2002) 2.09
C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol (2004) 2.08
Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. BMJ (2014) 2.06
A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes (2004) 2.03
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation (2005) 2.02
Association between the Part D coverage gap and adverse health outcomes. J Am Geriatr Soc (2012) 1.99